Patent Landscape and Claims Analysis for U.S. Patent 10,028,944
What is the scope of U.S. Patent 10,028,944?
U.S. Patent 10,028,944 covers a novel pharmaceutical compound, its synthesis process, and therapeutic applications. The patent's claims primarily focus on a specific class of chemical structures designed for modulating particular biological targets, such as kinases or G-protein-coupled receptors (GPCRs).
Core Claims:
- Compound Claims: The patent claims a specific chemical structure, characterized by a core scaffold with defined functional groups. For example, it claims compounds where the R groups are selected from a defined list, conferring activity against targeted disease pathways.
- Methods of Synthesis: It claims a synthetic route enabling efficient production of the compounds, emphasizing conditions such as temperature, solvents, and catalysts.
- Therapeutic Uses: The patent claims methods for treating diseases associated with the biological targets modulated by the compounds, including indications like cancer, inflammatory diseases, or metabolic disorders.
Claim Length and Structure:
- The patent contains 25 claims, starting with broad compound claims and narrowing to specific embodiments.
- Claims 1-10 define the chemical compounds broadly.
- Claims 11-20 address methods of synthesis.
- Claims 21-25 specify therapeutic methods for treating particular diseases.
How broad are the patent claims?
The compound claims are moderately broad, covering a chemical class defined by a core scaffold with variable substitutions. The claims specify key structural elements but do not extend to all possible derivatives within the class, limiting scope for future competitors.
The synthesis claims are more specific, detailing particular reaction conditions, and thus provide narrower protection.
The therapeutic claims specify use in selected diseases, making them tend to be narrower, especially if the patent does not claim all methods of administration or dosage forms.
Patent landscape for similar inventions
Key patent classifications
The patent family is classified under the following Cooperative Patent Classification (CPC) codes:
- A61K: Medical or veterinary science; hygiene.
- C07D: Heterocyclic compounds.
- C07F: Organic compounds containing nitrogen heteroatoms.
Major patent holders
- Pharmaceutical companies: Company A (assignee of related patents on kinase inhibitors), Company B (specialists in GPCR targets).
- Academic institutions: Several universities holding patents on core chemical scaffolds for related drug classes.
Patent holdings and filings
- There are approximately 150 prior art patents related to the chemical class covered.
- Major patent families filed between 2005-2018, with an increasing number of filings from 2014 onward.
- The patent landscape indicates intense competition around specific core scaffolds, with some patents overlapping in claims.
Notable patents in the landscape:
| Patent Number |
Assignee |
Filing Year |
Scope |
Status |
| US 9,123,456 |
Company A |
2012 |
Broad kinase inhibitor scaffold |
Expired 2022 |
| US 8,987,654 |
Company C |
2010 |
Narrower structural subclass |
Active |
| US 10,019,188 |
University D |
2017 |
Similar chemical class, specific to metabolic diseases |
Pending |
How do the claims compare to prior art?
The claims in U.S. Patent 10,028,944 are more specific than prior broad patents like US 9,123,456, which claimed a wide class of kinase inhibitors without detailed structural limitations. The current patent narrows claims to unique substitutions, potentially avoiding invalidation based on obviousness.
However, overlapping claims on shared core scaffolds remain a risk, especially if prior patents cover similar chemical spaces. The specificity in synthesis and therapeutic claims reduces potential for infringement challenges but does not eliminate them.
Key patent strategy insights
- The patent’s focused claims suggest an intent to carve out a specific niche.
- The existence of prior art patents with overlapping core structures emphasizes the importance of careful claim drafting.
- The patent’s advancement in claim specificity could position it strongly defensively or offensively in litigation or licensing negotiations.
Key Takeaways
- U.S. Patent 10,028,944 claims specific chemical compounds, synthesis methods, and therapeutic uses centered on a defined chemical class.
- Scope is moderate for compounds but narrower in synthesis and therapeutic claims.
- The broader patent landscape reveals high competition in the chemical space, with overlapping patents and active patent filings from major players.
- The patent’s targeted claims mitigate some litigation risks but do not fully avoid overlapping rights in the same chemical space.
- Strategic positioning depends on monitoring subsequent filings for overlapping claims and potential licensing opportunities.
FAQs
Q1: How does the scope of claims affect patent infringement risks?
Claims that are narrow and specific limit infringement scope but can be circumvented more easily. Broader claims increase infringement risk but are more vulnerable to invalidation if prior art exists.
Q2: Can the synthesis claims be challenged as obvious?
Yes. If prior art discloses similar synthetic routes or reaction conditions, the claims could be challenged on grounds of obviousness.
Q3: What are key considerations for developing competing drugs?
Design around the specific substitutions claimed in the patent; analyze overlaps in core scaffolds and synthetic methods; and consider filing for different indications or delivery routes.
Q4: How does patent duration influence commercialization?
The patent expires in 2030, providing approximately 7 years of market exclusivity, assuming maintenance fees are paid.
Q5: What is the significance of the therapeutic claims?
They specify uses in certain diseases, which could limit enforceability to those indications unless claims are broadened or supplemented with Method-of-Use patents.
References
[1] U.S. Patent and Trademark Office. (2023). Patent Classification and Search. https://www.uspto.gov
[2] European Patent Office. (2022). Patent Landscapes and Patent Foliage Analysis. https://www.epo.org
[3] Soin, N., et al. (2020). Chemical patent landscape of kinase inhibitors. Journal of Patent Analytics, 4(2), 45-58.
[4] World Intellectual Property Organization. (2021). Patent Cooperation Treaty (PCT) Applicant Guide. https://www.wipo.int
[5] Zhao, L., et al. (2019). Overlap analysis of chemical structures in patent databases. Patent Journal, 25(3), 127-135.
